Venture Life Group (VLG) H2 2025 TU earnings summary

Executive summary

• Revenues for the twelve months ended 31 December 2025 rose 32.0% to £35.1 million compared to the previous year, with proforma growth of 11.1% year-over-year, driven by both price and volume increases.

• The business has transitioned to a pure branded consumer healthcare model, following the disposal of its CDMO operations, and is now focused on brand growth and strategic partnerships.

• Increased investment in advertising and promotion, particularly in the UK, has driven significant revenue growth, especially in women's health brands.

• The company is actively pursuing earnings-enhancing M&A opportunities in complementary health sectors.

Financial highlights

• UK revenues grew 20.7% to £25.7 million on a proforma basis, while international revenues declined 8.7% to £9.4 million due to order timing and distributor changes.

• Power Brands revenue increased 14.9% to £33.1 million, with notable growth in Balance Activ (up 37.0%), Earol (up 11.5%), and Health & Her/Him (up 44% proforma).

• Net cash position at 31 December 2025 was £34.4 million, up from £2.0 million at 30 June 2025.

• £1.1 million returned to shareholders via share buybacks, acquiring approximately 1.7 million shares.

Outlook and guidance

• Board remains confident in achieving management's revenue and Adjusted EBITDA expectations for the seventeen-month period ending 31 May 2026.

• New product development pipeline and digital transformation initiatives are expected to drive future revenue growth.